9 Meters Biopharma Inc
OTC:NMTRQ

Watchlist Manager
9 Meters Biopharma Inc Logo
9 Meters Biopharma Inc
OTC:NMTRQ
Watchlist
Price: 0.0001 USD
Market Cap: $1.4k

9 Meters Biopharma Inc
Research & Development

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

9 Meters Biopharma Inc
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
9 Meters Biopharma Inc
OTC:NMTRQ
Research & Development
-$32.4m
CAGR 3-Years
-29%
CAGR 5-Years
-38%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Research & Development
-$14.7B
CAGR 3-Years
-1%
CAGR 5-Years
-4%
CAGR 10-Years
-5%
Bristol-Myers Squibb Co
NYSE:BMY
Research & Development
-$9.7B
CAGR 3-Years
-1%
CAGR 5-Years
-2%
CAGR 10-Years
-7%
Pfizer Inc
NYSE:PFE
Research & Development
-$10.1B
CAGR 3-Years
6%
CAGR 5-Years
-4%
CAGR 10-Years
-2%
Merck & Co Inc
NYSE:MRK
Research & Development
-$15.5B
CAGR 3-Years
-10%
CAGR 5-Years
-10%
CAGR 10-Years
-8%
Eli Lilly and Co
NYSE:LLY
Research & Development
-$12.6B
CAGR 3-Years
-21%
CAGR 5-Years
-17%
CAGR 10-Years
-11%
No Stocks Found

9 Meters Biopharma Inc
Glance View

Market Cap
1.4k USD
Industry
Pharmaceuticals

9 Meters Biopharma, Inc. is a clinical-stage biopharmaceutical company, which focuses on rare and unmet needs in gastroenterology. The company is headquartered in Raleigh, North Carolina and currently employs 21 full-time employees. The company went IPO on 2016-07-08. The firm is focused on developing treatments for people with rare digestive diseases, gastrointestinal (GI) conditions with unmet needs. Its pipeline includes Vurolenatide, Larazotide, NM-102, NM-003, NM-136 and NM-004. Vurolenatide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist that combines exenatide with an extended half-life technology for treatment of short bowel syndrome (SBS). Larazotide is an 8-amino acid peptide formulated into an orally administered capsule for treatment of celiac disease. NM-102 is a small molecule peptide, is being developed as a potential microbiome modulator and is undergoing an indication selection process. NM-003 is a long-acting GLP-2 receptor agonist, for prevention of acute graft versus host disease. NM-004 is a double-cleaved mesalamine with an immunomodulator for pediatric ulcerative colitis.

NMTRQ Intrinsic Value
Not Available

See Also

What is 9 Meters Biopharma Inc's Research & Development?
Research & Development
-32.4m USD

Based on the financial report for Mar 31, 2023, 9 Meters Biopharma Inc's Research & Development amounts to -32.4m USD.

What is 9 Meters Biopharma Inc's Research & Development growth rate?
Research & Development CAGR 5Y
-38%

Over the last year, the Research & Development growth was -19%. The average annual Research & Development growth rates for 9 Meters Biopharma Inc have been -29% over the past three years , -38% over the past five years .

Back to Top